Telomir Pharmaceuticals released preclinical data suggesting that its lead compound, Telomir-1, can reverse multiple hallmarks of cellular decline in human cell lines and show disease-modifying effects in animal models.
According to the company, in vitro studies conducted with human cell lines showed that Telomir-1 improves mitochondrial activity, reduces oxidative stress, restores calcium balance, protects from metal-induced toxicity, and boosts cell viability under stress.
In a rare disease model, the company claims that Telomir-1 reversed neurological, liver, and kidney dysfunction in an animal model of Wilson’s disease. Effects reportedly included reductions in copper accumulation, normalization of liver biomarkers (ALT, AST, bilirubin), improved survival, and histopathological recovery.
Telomir is preparing to submit an Investigational New Drug (IND) application by year end and plans human clinical trials in the first half of 2026. The company said that expansion targets include autism, spasmodic dysphonia, and other degenerative or age-related conditions.
These results remain at the preclinical stage, and Telomir’s claims await validation in further animal studies and human trials.
